Whitehawk Therapeutics, Inc. Cash Flow Conversion Efficiency
Whitehawk Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Whitehawk Therapeutics, Inc. (WHWK) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.38 Million) by net assets ($157.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Whitehawk Therapeutics, Inc. (2019–2024)
Cash flow conversion efficiency of Whitehawk Therapeutics, Inc. from 2019 to 2024. This chart illustrates how Whitehawk Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Whitehawk Therapeutics, Inc. stock price for real-time trading data and today's change.
Whitehawk Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Whitehawk Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Whitehawk Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Whitehawk Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see WHWK market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HIM International Music
TWO:8446
|
0.018x |
|
ABC Taiwan Electronics
TWO:3236
|
0.057x |
|
Digital Aria Co Ltd
KQ:115450
|
-0.019x |
|
Ilex Medical
TA:ILX
|
0.070x |
|
TIZIANA LIFE SCIENCES LTD
F:0RP
|
N/A |
|
Medigen Biotechnology
TWO:3176
|
-0.004x |
|
Kolmar BNH Co. Ltd
KQ:200130
|
0.049x |
|
Wellcall Holdings Bhd
KLSE:7231
|
0.095x |
Annual Cash Flow Conversion Efficiency for Whitehawk Therapeutics, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Whitehawk Therapeutics, Inc. from 2019 to 2024. Review Whitehawk Therapeutics, Inc. free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-59.55 Million | -1.135x | -100.08% |
| 2023-12-31 | $105.19 Million | $-59.66 Million | -0.567x | -80.96% |
| 2022-12-31 | $158.38 Million | $-49.64 Million | -0.313x | -90.67% |
| 2021-12-31 | $136.41 Million | $-22.42 Million | -0.164x | -116.09% |
| 2020-12-31 | $-12.43 Million | $-12.70 Million | 1.022x | +22.50% |
| 2019-12-31 | $-9.09 Million | $-7.58 Million | 0.834x | -- |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more